BioSpace News Archive

Novartis Pharmaceuticals Corporation announced a Consumer Product Safety Commission -approved corrective action plan after identifying certain blister card packages of SANDIMMUNE 100-mg soft gelatin capsules and NEORAL MODIFIED 100-mg soft gelatin capsules distributed in the US do not meet child-resistant packaging requirements, posing a potential risk of harm if children open the package and swallow the medicine.

The U.S. Pharmacopeia is providing free technical assistance to developers of medical treatments such as antiviral drugs and vaccines that can support the public health response to the COVID-19 pandemic.

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.

JumpStart NEXT Fund Leads Round, Senior Partner Rem Harris Joins Board of Directors

Allevant Solutions, a leader in Transitional Care programs for CAHs is offering a 5-part webinar series and learning modules to help CAHs prepare for additional patients by providing Transitional Care using swing beds, as well as to help reduce provider stress and burnout.

College of American Pathologists President Patrick Godbey, MD, FCAP issued the following statement after the release of the Verified Innovative Testing in American Laboratories Act of 2020 on March 18

Biohaven Pharmaceutical Holding announced today that the Company’s received fast track designation from FDA

Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three and 12 months ended December 31, 2019 after the market close

Today, the Cystic Fibrosis Foundation announced a new research award of up to $5 million to Armata Pharmaceuticals to conduct a Phase 1b/2 clinical trial to test the safety and tolerability of bacteriophage (phage therapy) in Pseudomonas aeruginosa infections in people living with cystic fibrosis (CF).

IMV Inc. announced that it has entered into an equity distribution agreement, dated March 18, 2020, with Piper Sandler & Co. as agent, pursuant to which the Company may, from time to time sell, through “at-the-market” offerings with Piper Sandler acting as sales agent, on the Nasdaq Capital Market such number of common shares as would have an aggregate offering price of up to US$30 million under the ATM Prospectus Supplement.